Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women
2010-020840-36Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of group b streptococcus trivalent vaccine in Streptococcus agalactiae infection (GBS) and Streptococcus agalactiae sepsis (2 arms), sponsored by Novartis. Primary endpoint: Placental transfer ratio of anti-group B Streptococcus CPS antibodies. Started Apr 2011; status: completed.
02
Drugs
group b streptococcus trivalent vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)Streptococcus agalactiae sepsis
Beyond the preview
Go deeper on 2010-020840-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020840-36.